Introduction
============

Lung cancer remains the most frequent cause of cancer-related death in developed countries ([@b1-ijo-49-05-1870]). Approximately 80% of lung cancers are categorized as non-small cell lung cancer (NSCLC), and NSCLC is divided into four major subtypes pathologically: adenocarcinoma, squamous cell carcinoma (SCC), large cell carcinoma and neuroendocrine cancer ([@b2-ijo-49-05-1870]). Development of targeted molecular therapies has remarkably improved the overall survival of patients with adenocarcinoma ([@b3-ijo-49-05-1870]--[@b6-ijo-49-05-1870]). In contrast, targeted molecular therapies have offered few benefits in the management of lung SCC ([@b7-ijo-49-05-1870]). Therefore, there is a need for effective treatment options based on current genomic approaches for lung SCC.

After the human genome sequencing era, the discovery of an extremely large number of non-coding RNAs conceptually transformed cancer research. MicroRNAs (miRNAs) are small non-coding RNAs involved in the repression or degradation of target RNA transcripts in a sequence-dependent manner ([@b1-ijo-49-05-1870],[@b2-ijo-49-05-1870]). The ability of miRNAs is unique; a single miRNA may regulate a vast number of protein-coding or non-coding RNAs in human cells. Therefore, aberrantly expressed miRNAs may upset tightly regulated cellular RNA networks. This failing of the RNA network contributes to cancer development, aggressiveness and drug resistance ([@b3-ijo-49-05-1870]--[@b5-ijo-49-05-1870]). In fact, aberrantly expressed miRNAs have been reported in various types of human cancers, including lung SCC ([@b6-ijo-49-05-1870]--[@b8-ijo-49-05-1870]). Based on miRNA expression signatures, we identified tumor-suppressive miRNAs and the cancer RNA networks regulated by these miRNAs ([@b9-ijo-49-05-1870]--[@b11-ijo-49-05-1870]). We hypothesize that elucidation of tumor-suppressive miRNA-regulated oncogenic networks will provide new insights into the potential molecular mechanisms of lung SCC.

In our earlier studies determining miRNA expression signatures, we showed that *miRNA-218* was significantly downregulated in several types of cancer tissues ([@b12-ijo-49-05-1870]--[@b15-ijo-49-05-1870]). Our previous studies also demonstrated that downregulation of *miR-218* enhanced overexpression of extracellular matrix (ECM) protein components or actin-related proteins, and this promoted cancer cell migration and invasion ([@b16-ijo-49-05-1870]--[@b18-ijo-49-05-1870]). Tumor-suppressive roles of *miR-218* were reported in several types of cancer. However, the impact of *miR-218* on lung SCC remains ambiguous.

The aim of the present study was to investigate the functional significance of *miR-218* in lung SCC and to identify molecular targets regulated by this miRNA. We found that restoration of *miR-218* significantly suppressed cancer cell migration and invasion. Using luciferase reporter assay, tumor protein D52 (*TPD52*) was shown to be directly regulated by *miR-218*. Overexpression of *TPD52* was observed in lung SCC clinical specimens and downregulation of the *TPD52* gene significantly inhibited cancer cell aggressiveness. *miR-218/ TPD52*-regulated RNA networks may provide new insights into the potential mechanisms of lung SCC pathogenesis.

Materials and methods
=====================

Clinical specimens, cancer cell lines and RNA extraction
--------------------------------------------------------

In all, 31 lung SCC specimens and 24 non-cancerous lung specimens were obtained from patients who underwent thoracic surgery at Kagoshima University Hospital from 2010 to 2013. The present study was approved by the Institutional Review Board for Clinical Research of the Kagoshima University School of Medicine. Prior written informed consent and approval were obtained from each patient. [Table I](#tI-ijo-49-05-1870){ref-type="table"} describes the patient background and clinical characteristics of collected specimens. Samples were staged using the TNM scheme according to the International Association for the Study of Lung Cancer and were graded histologically ([@b19-ijo-49-05-1870]). These archival formalin-fixed paraffin-embedded (FFPE) samples were subsequently studied by qRT-PCR analysis and immunohistochemistry as previously described ([@b9-ijo-49-05-1870]--[@b11-ijo-49-05-1870]).

The human lung SCC cell lines EBC-1 and SK-MES-1 were acquired from the Japanese Cancer Research Resources Bank (Osaka, Japan) and the American Type Culture Collection ATCC; Manassas, VA, USA), respectively.

Total RNA was isolated using Isogen II (code no: 311-07361; Nippon Gene, Co., Ltd., Tokyo, Japan) as directed by the manufacturer.

Quantitative reverse transcription PCR (qRT-PCR)
------------------------------------------------

PCR quantification was performed as previously described ([@b9-ijo-49-05-1870]--[@b11-ijo-49-05-1870]). The expression of *miR-218* was determined using stem-loop RT-PCR as directed by the manufacturer (P/N: 000521; Applied Biosystems, Foster City, CA, USA). The TaqMan probe and *TPD52* primers were from Assay-on-Demand™ Gene Expression products (P/N: Hs00893105_m1; Applied Biosystems). For quantification, miRNA and mRNA data were normalized against human *RNU48* (P/N: 001006; Applied Biosystems) and *GUSB* (P/N: Hs99999908_m1; Applied Biosystems), respectively.

Transfection of mature miRNA and small interfering RNA (siRNA)
--------------------------------------------------------------

Pre-miR™ miRNA precursors for *miR-218* (*hsa-miR-218-5p*, P/N: AM1 7100; Applied Biosystems) and negative control miRNA (P/N: AM 17111; Applied Biosystems), Stealth Select RNAi siRNA, si-*TPD52* (P/N: HSS120730 and HSS120731; Invitrogen, Carlsbad, CA, USA), and negative control siRNA (P/N: 4390843; Invitrogen) were used in this study. EBC-1 and SK-MES-1 cells in Opti-MEM medium (cat. no. 31985070; Thermo Fisher Scientific, Waltham, MA, USA) were transfected with Lipofectamine RNAiMAX transfection reagent (P/N: 56532; Invitrogen) with 10 nM mature miRNA or siRNA.

Cell proliferation, migration and invasion assays
-------------------------------------------------

Cell proliferation was determined by XTT assay using Cell Proliferation kit (SKU: 20-300-1000; Biological Industries, Kibbutz Beit Haemek, Israel). Cell migration activity was analyzed by wound-healing assay, and cell invasion was analyzed using Corning BioCoat Matrigel Invasion chamber (cat. no. 354480; BD Biosciences, Bedford, MA, USA). The cell proliferation, migration, and invasion assays were carried out as previously described ([@b9-ijo-49-05-1870]--[@b11-ijo-49-05-1870]).

Identification of putative miR-218 target genes in lung SCC cells
-----------------------------------------------------------------

Genome-wide gene expression analysis of *miR-218*-transfected EBC-1 cells was performed (accession number: GSE77790). Putative *miR-218*-regulated genes were identified by searching the TargetScan database (<http://www.targetscan.org/>). We then examined the expression levels of putative *miR-218* targets in lung SCC clinical expression data from the GEO database (accession number: GSE19188). Oligo-microarray procedures and data mining methods were conducted as previously described ([@b20-ijo-49-05-1870],[@b21-ijo-49-05-1870]).

Western blot analysis
---------------------

Cells were harvested 96 h after transfection, and proteins were extracted from lysed cells. Protein lysates (20 μg) were separated on NuPAGE 4--12% Bis-Tris gels (cat. no. NP0323BOX; Invitrogen) before transfer of proteins to a polyvinylidene fluoride membrane. Immunoblotting was performed using diluted primary anti-TPD52 antibodies (1:250 dilution; Human Protein Atlas no. HPA028427; Atlas Antibodies, Stockholm, Sweden) and anti-GAPDH antibodies (1:10,000 dilution; cat. no. MAB374; Chemicon International, Inc., Temecula, CA, USA). These assays were carried out as previously described ([@b9-ijo-49-05-1870]--[@b11-ijo-49-05-1870]).

Plasmid construction and dual-luciferase reporter assay
-------------------------------------------------------

The procedure for the dual-luciferase reporter assay was previously described ([@b9-ijo-49-05-1870]--[@b11-ijo-49-05-1870]). A partial sequence of the wild-type *TPD52* 3′-UTR containing the *miR-218* target site or the *TPD52* 3′-UTR partial sequence lacking the *miR-218* target site was cloned into the psiDHECK-2 vector between the *Xho*I-*Pme*I restriction sites in the 3′-UTR of the *hRluc* gene (cat. no. C8021; Promega, Madison, WI, USA).

Immunohistochemistry
--------------------

The expression status of *TPD52* in lung SCC clinical specimens (BC04002; US Biomax, Inc., Rockville, MD, USA) was confirmed via immunohistochemistry using an UltraVision Detection system (cat. no. TP-015-HD, Thermo Fisher Scientific) according to the manufacturer\'s protocol. Tissues were incubated with primary rabbit polyclonal anti-*TPD52* antibodies (1:3,000 dilution; HPA028427) then treated with biotinylated goat anti-rabbit secondary antibodies. Antibodies were visualized using diaminobenzidine hydrogen peroxidase as the chromogen, and slides were counterstained with 0.5% hematoxylin.

Identification of downstream targets regulated by TPD52 in lung SCC
-------------------------------------------------------------------

Gene expression analysis using si-*TPD52*-transfected EBC-1 cells identified molecular targets regulated by *TPD52* in lung SCC cells. Microarray expression profiles of si-*TPD52* transfectants were compiled and deposited into the GEO database (accession number: GSE82108).

Statistical analysis
--------------------

RT-PCR results were analyzed using Mann-Whitney U tests to evaluate the relationships between the 2 groups, while Bonferroni-adjusted Mann-Whitney U tests were used to analyze the relationships among three or more variables. All analyses were performed using Expert StatView (version 5; SAS Institute Inc., Cary, NC, USA).

Results
=======

Expression of miR-218 in lung SCC tissues and cell lines
--------------------------------------------------------

To confirm the miRNA expression signatures of lung SCC cells, we evaluated the expression level of *miR-218* in lung SCC tissues (n=31) and non-cancerous lung tissues (n=24). The patient clinicopathological features are summarized in [Table I](#tI-ijo-49-05-1870){ref-type="table"}. The expression level of *miR-218* was significantly downregulated in cancer tissues compared to non-cancerous tissues (P\<0.0001; [Fig. 1A](#f1-ijo-49-05-1870){ref-type="fig"}). Expression of *miR-218* in EBC-1 and SK-MES-1 cell lines was also lower than in non-cancerous lung tissues ([Fig. 1A](#f1-ijo-49-05-1870){ref-type="fig"}).

Effects of miR-218 restoration on the proliferation, migration and invasion of EBC-1 and SK-MES-1 cells
-------------------------------------------------------------------------------------------------------

To investigate the antitumor activity of *miR-218*, we performed gain-of-function assays using miRNA transfection into EBC-1 and SK-MES-1 cells. Cell proliferation assays showed that cancer cell growth was slightly inhibited in *miR-218* transfectants compared with mock- or miR control-transfected EBC-1 and SK-MES-1 cells ([Fig. 1B](#f1-ijo-49-05-1870){ref-type="fig"}). Cancer cell migration and invasion activities were significantly inhibited in *miR-218* transfectants compared with mock- or miR-control-transfectants (P\<0.0001; [Fig. 1C and D](#f1-ijo-49-05-1870){ref-type="fig"}).

Identification of putative targets regulated by miR-218 in EBC-1 cells
----------------------------------------------------------------------

To identify putative targets of *miR-218*, we employed a combination of *in silico* analysis, genome-wide gene expression analysis and analysis of gene expression in clinical specimens using the GEO database. First, we identified 513 genes downregulated by *miR-218* transfection into EBC-1 cells (log~2~ ratio \<−1.0). Among these 513 genes, 163 genes have putative *miR-218* binding sites in their 3′-UTR regions according to the TargetScan database. Next, we cross-referenced these genes with genes upregulated (fold change \>1.5) in NSCLC clinical specimens from the GEO gene expression data set (accession number: GSE19188). A total of 36 candidate genes were identified as putative target genes of *miR-218* regulation in lung SCC ([Table II](#tII-ijo-49-05-1870){ref-type="table"}). [Fig. 2](#f2-ijo-49-05-1870){ref-type="fig"} shows our strategy for selecting putative *miR-218* target genes.

In the present study, we focused on the *TPD52* gene, investigating *TPD52* function and downregulated *TPD52*-mediated pathways.

TPD52 is directly targeted by miR-218 in lung SCC cells
-------------------------------------------------------

First, we measured the expression of *TPD52*/TPD52 using quantitative RT-PCR and western blotting to determine whether restoration of *miR-218* in EBC-1 and SK-MES-1 cells suppressed the expression of *TPD52*/TPD52. As shown in [Fig. 3A and B](#f3-ijo-49-05-1870){ref-type="fig"}, the expression levels of *TPD52*/TPD52 were markedly repressed by *miR-218* transfection compared with mock- or miR-control-transfected cells.

Next, we used luciferase reporter assays to determine whether *miR-218* directly binds to the 3′-UTR of *TPD52* mRNA. We used vectors encoding either partial wild-type sequences of the 3′-UTR of *TPD52* including the predicted *miR-218* target sites (positions 52--58, 778--784, 940--946 of the *TPD52* 3′-UTR), or deletion vectors lacking these sites ([Fig. 3C](#f3-ijo-49-05-1870){ref-type="fig"}). The luminescence intensities were significantly reduced by transfection with *miR-218* and the vector carrying the wild-type 3′-UTR of *TPD52*, whereas transfection with the deletion vector blocked the decrease of luminescence in EBC-1 cells (P\<0.0001). Thus, *miR-218* bound directly to three sites in the 3′-UTR of *TPD52* ([Fig. 3D--F](#f3-ijo-49-05-1870){ref-type="fig"}).

Effects of TPD52 silencing on cell proliferation, migration and invasion in lung SCC cell lines
-----------------------------------------------------------------------------------------------

We performed loss-of-function studies using si-*TPD52* to investigate the oncogenic function of *TPD52* in lung SCC cells. First, we measured the knockdown efficiency of si-*TPD52* transfection in EBC-1 and SK-MES-1 cells. RT-PCR and western blotting showed that two siRNAs (si-*TPD52*-1 and si-*TPD52*-2) could effectively reduce the expression of *TPD52*/TPD52 in EBC-1 and SK-MES-1 cells ([Fig. 4A and B](#f4-ijo-49-05-1870){ref-type="fig"}).

Next, we carried out functional assays using these two siRNAs. XTT assays demonstrated that cell proliferation was inhibited by si-*TPD52* transfection only in SK-MES-1 cells ([Fig. 4C](#f4-ijo-49-05-1870){ref-type="fig"}). Cell migration and invasion activities were significantly inhibited by si-*TPD52* transfection in both EBC-1 and SK-MES-1 cells in comparison with mock- or negative-control transfectants ([Fig. 4D and E](#f4-ijo-49-05-1870){ref-type="fig"}).

TPD52 was strongly expressed in clinical lung SCC specimens
-----------------------------------------------------------

To analyze whether *TPD52* was upregulated in lung SCC clinical specimens, we carried out immunohistochemical staining of lung SCC and non-cancerous lung tissues. Thirty specimens were stained in this study (20 lung SCC specimens and 10 non-cancerous tissues); all lung SCC specimens stained moderately or strongly, whereas all non-cancerous specimens stained weakly or negatively for TPD52 ([Table III](#tIII-ijo-49-05-1870){ref-type="table"} and [Fig. 5](#f5-ijo-49-05-1870){ref-type="fig"}).

Identification of TPD52-mediated downstream pathways in lung SCC cells
----------------------------------------------------------------------

To identify the downstream genes regulated by *TPD52*, genome-wide gene expression analysis and *in silico* analysis were performed in lung SCC cells transfected with si-*TPD52*. A total of 2,278 genes were identified as downregulated in si-*TPD52*-transfected EBC-1 cells compared with the control (log~2~ ratio \<−0.5). Among them, 215 genes were upregulated in NSCLC specimens in the GEO database (accession number: GSE19188). We categorized the 215 genes according to KEGG pathways, and 7 pathways were identified as significantly enriched pathways ([Table IV](#tIV-ijo-49-05-1870){ref-type="table"}). [Fig. 6](#f6-ijo-49-05-1870){ref-type="fig"} shows our strategy for selecting TPD52-mediated downstream pathways. Among these pathways, we focused on the 'Cell cycle pathway', 'DNA replication pathways' and 'p53 signaling pathway'. Genes involved in these pathways are listed in [Table V](#tV-ijo-49-05-1870){ref-type="table"}.

Discussion
==========

A single miRNA can regulate an extremely large number of protein-coding or non-coding RNAs. Thus, aberrant expression of miRNAs disrupts the RNA network in cancer cells. Identification of aberrantly expressed miRNAs and the novel cancer networks they regulate is a research trend of the post-genome-sequencing era. Recent evidence shows that disruption of normally-regulated RNA networks by aberrantly expressed miRNAs triggers cancer cell development, progression and metastasis ([@b3-ijo-49-05-1870],[@b4-ijo-49-05-1870]). Our recent studies of miRNA expression signatures in various cancers indicated that *miR-218* is frequently downregulated in cancers ([@b9-ijo-49-05-1870]--[@b11-ijo-49-05-1870]). Investigating *miR-218*-regulated RNA networks in lung SCC is the first step in construction of a new treatment strategy for the disease.

Our current data showed that expression of *miR218* was significantly reduced in lung SCC specimens. The mature form of *miR-218* is generated from two separate loci, *miR-218-1* and *miR-218-2*, which are located on chromosomes 4p15.31 and 5q35.1 within the introns of *SLIT2* and *SLIT3*, respectively ([@b22-ijo-49-05-1870]). Several lines of evidence suggest that *miR-218* is frequently downregulated in various cancers ([@b17-ijo-49-05-1870],[@b18-ijo-49-05-1870],[@b23-ijo-49-05-1870],[@b24-ijo-49-05-1870]). In this study, ectopic expression of *miR-218* significantly inhibited cancer cell migration and invasion, suggesting this miRNA suppresses metastasis-promoting genes. Our previous studies showed that antitumor effects of *miR-218* explicitly contribute to migration and invasion in head and neck cancer, cervical cancer, renal cell carcinoma and prostate cancer ([@b17-ijo-49-05-1870],[@b18-ijo-49-05-1870],[@b23-ijo-49-05-1870],[@b24-ijo-49-05-1870]). Interestingly, *miR-21*8-regulated genes were involved in ECM-related components such as collagens, laminins and integrins ([@b17-ijo-49-05-1870],[@b18-ijo-49-05-1870],[@b23-ijo-49-05-1870],[@b24-ijo-49-05-1870]). Accumulating evidence indicates that the interaction of cancer cells with their microenvironment influences the initiation, development and metastasis of cancer cells ([@b25-ijo-49-05-1870],[@b26-ijo-49-05-1870]). Overexpression of ECM components and activation of ECM-integrin signaling were observed in several types of cancers and shown to activate cancer cell aggressiveness ([@b27-ijo-49-05-1870]). The discovery of tumor-suppressive *miR-218*-regulated genes and pathways may provide important insights into the potential mechanisms of lung SCC metastasis.

To better understand lung SCC development and metastasis, we identified *miR-218* target genes using a combination of *in silico* and genome-wide gene expression analyses. We have identified antitumor miRNA-regulated oncogenes and novel cancer networks using this strategy ([@b9-ijo-49-05-1870]--[@b11-ijo-49-05-1870]). In the present study, a total of 36 putative target genes of *miR-218* were identified. Among these genes, we demonstrated that *LOXL2* (lysyl oxidase homolog 2) was directly regulated by *miR-218* in head and neck cancer and prostate cancer ([@b28-ijo-49-05-1870]). Another group showed direct regulation of *BIRC5* (baculoviral IAP repeat containing 5) by *miR-218* in cervical cancer ([@b29-ijo-49-05-1870]). These findings show the effectiveness of our strategy in identifying target genes of *miR-218*-regulation in cancer cells.

In the present study, we focused on *TPD52* and investigated the functional significance of this gene in lung SCC. *TPD52* was initially cloned through differential screening using a breast cancer cDNA library ([@b30-ijo-49-05-1870]). This cDNA clone had novel sequences and was expressed in breast and basal cell carcinomas ([@b30-ijo-49-05-1870]). Interestingly, this gene is located on the human chromosome 8q21.13, a frequently observed region of chromosomal amplification in several types of cancers ([@b31-ijo-49-05-1870]--[@b33-ijo-49-05-1870]). In lung adenocarcinoma, chromosome 8q21.13, which includes *TPD52*, was one of the most notable amplified genomic regions ([@b34-ijo-49-05-1870]). A vast number of studies showed that *TPD52* is overexpressed both at the mRNA and protein levels in several cancers. Likewise, overexpression of *TPD52* was reported in small cell lung cancer, lung adenocarcinoma and lung SCC ([@b35-ijo-49-05-1870]--[@b37-ijo-49-05-1870]). The influence of smoking is important in lung cancer pathogenesis. Expression levels of *TPD52* were enhanced in airway epithelial cells in smokers with lung cancer compared to smokers without cancer ([@b38-ijo-49-05-1870]). The functional roles of *TPD52* were investigated using overexpression or knockdown analytical methods. Ectopic expression of mouse *TPD52* in 3T3 fibroblasts resulted in a transformed phenotype that progressed to metastasis ([@b39-ijo-49-05-1870]). Several studies have shown that increased expression of *TPD52* enhances the proliferation of prostate cancer cell lines under both normal and androgen-resistant conditions ([@b40-ijo-49-05-1870],[@b41-ijo-49-05-1870]). Other studies showed that *TPD52* knockdown increases apoptotic cell death in ERBB2-amplified breast cancer cell lines ([@b33-ijo-49-05-1870]). These findings suggest that over-expression of *TPD52* enhances cancer cell aggressiveness and contributes to several oncogenic pathways.

Recently, several studies demonstrated that *TPD5*2 expression is regulated by several miRNAs in cancer cells. Downregulation of *TPD52* expression was observed by *miR-107* and *miR-185* transfection into non-small cell lung cancer cells and *miR-34a* transfection into colorectal cancer cells ([@b42-ijo-49-05-1870],[@b43-ijo-49-05-1870]). Our previous data showed that the tumor-suppressive *miR-224* directly regulates oncogenic *TPD52* in prostate cancer cells, and silencing *TPD52* results in significant reductions in cancer cell migration and invasion in prostate cancer cells ([@b44-ijo-49-05-1870]). More recently, *miR-218* was shown to directly regulate *TPD52* in prostate cancer cells ([@b45-ijo-49-05-1870]). These data agree with our present report in lung SCC and support our conclusions. Control of *TPD52* expression by miRNAs is a novel molecular mechanism of cancer cells, and further investigation of the miRNA-TPD52 axis is needed.

In the present study, we identified *TPD52*-mediated cancer pathways using genome-wide gene expression analysis of si-*TPD52*-transfected lung SCC cells. Our data showed that several pathways were identified downstream of *TPD52* pathways, such as the 'Cell cycle pathway', 'DNA replication pathway' and 'p53 signaling pathway'. The genes involved in these pathways were critical regulators of genomic stability and were mitotic checkpoint genes ([@b46-ijo-49-05-1870],[@b47-ijo-49-05-1870]). The functional insights obtained in the current studies indicated that several cell cycle kinases, such as TTK, BUB1 and PLK1, were multi-functional enzymes and contributed to cancer cell migration, invasion and metastasis ([@b48-ijo-49-05-1870]--[@b50-ijo-49-05-1870]). The protein kinase TTK promoted the cell proliferation and migration through activation of AKT-mTOR and MDM2-p53 signaling pathways in hepatocellular carcinoma cells ([@b48-ijo-49-05-1870]). Using the siRNA screen of the human kinome revealed that a serine/threonine kinase BUB1 acted as an essential mediator of TGFβ-dependent signaling ([@b49-ijo-49-05-1870]). This study demonstrated that BUB1 interacted with both, TGFBRI and TGFBRII and promoted the TGFβ-dependent epithelial mesenchymal transition (EMT), cell migration and invasion ([@b49-ijo-49-05-1870]). PLK1 is a serine/threonine kinase and a pivotal player of cell cycle regulator ([@b50-ijo-49-05-1870]). Overexpression of PLK1 was observed in prostate cancer and involved in enhancing EMT and stimulation of cell migration and invasion ([@b50-ijo-49-05-1870]). In bladder cancer, CCNB2 was overexpressed in cancer cells and knockdown of *CCNB2* inhibited invasion and metastatic abilities ([@b51-ijo-49-05-1870]). These findings have supported our present data of knockdown of *TPD52* in lung cancer cells. Exploration of novel *TPD52*-mediated pathways may lead to the development of new treatment protocols for this disease.

In conclusion, expression of *miR-218* was frequently downregulated in lung SCC clinical specimens and appeared to function in anti-migration and anti-invasion roles through targeting of *TPD52*. Elucidation of *miR-218*-regulated cancer networks should provide new information on potential therapeutic targets in the treatment of lung SCC development and metastasis.
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![The expression of *miR-218* in lung SCC and its ectopic effects on EBC-1 and SK-MES-1 cancer cell lines. (A) Expression levels of *miR-218* in lung SCC clinical specimens and cell lines (EBC-1 and SK-MES-1) were determined using qRT-PCR. Data were normalized to *RNU48* expression. (B) Cell growth was determined using XTT assays 72 h after transfection with 10 nM *miR-218*. ^\*^P\<0.0001. (C) Cell migration activity was determined using wound-healing assays. ^\*^P\<0.0001. (D) Cell invasion activity was determined using Matrigel invasion assays. ^\*^P\<0.0001.](IJO-49-05-1870-g00){#f1-ijo-49-05-1870}

![Flow chart illustrating the analysis strategy for *miR-218* target genes in lung SCC cells.](IJO-49-05-1870-g01){#f2-ijo-49-05-1870}

![Direct regulation of *TPD52* by *miR-218* in lung SCC cells. (A) *TPD52* mRNA expression was evaluated by qRT-PCR in EBC-1 and SK-MES-1 cells 72 h after transfection with *miR-218*. *GUSB* was used as an internal control. ^\*^P\<0.0001. (B) TPD52 protein expression in EBC-1 and SK-MES-1 cells was evaluated using western blotting 72 h after transfection with *miR-218*. GAPDH was used as a loading control. (C) Putative *miR-218* binding sites in the 3′-UTR of *TPD52* mRNA. (D--F) Dual luciferase reporter assays using vectors encoding putative *miR-218* target sites in the *TPD52* 3′-UTR for both wild-type and deleted regions. Normalized data were calculated as *Renilla*/firefly luciferase activity ratios. ^\*^P\<0.0001.](IJO-49-05-1870-g02){#f3-ijo-49-05-1870}

![Effects of *TPD52* silencing in lung SCC cell lines. (A) *TPD52* mRNA expression in EBC-1 and SK-MES-1 cells was evaluated by qRT-PCR 72 h after transfection with si-*TPD52*-1 and si-*TPD52*-2. *GUSB* was used as an internal control. (B) TPD52 protein expression in EBC-1 and SK-MES-1 cells was evaluated by western blot analysis 72 h after transfection with *miR-218*. GAPDH was used as a loading control. (C) Cell proliferation was determined using XTT assays 72 h after transfection with 10 nM si-*TPD52*-1 or si-*TPD52*-2. ^\*^P\<0.0001. (D) Cell migration activity was determined by wound-healing assays. ^\*^P\<0.0001. (E) Cell invasion activity was determined using Matrigel invasion assays. ^\*^P\<0.0001.](IJO-49-05-1870-g03){#f4-ijo-49-05-1870}

![(A--D). Immunohistochemical staining of TPD52 in lung SCC specimens. Differences in TPD52 expression were observed between cancer lesions and non-cancerous tissues in the same field. Normal lung specimens stained weakly or negatively for TPD52.](IJO-49-05-1870-g04){#f5-ijo-49-05-1870}

![Flow chart illustrating the strategy for identifying *TPD52*-mediated downstream pathways.](IJO-49-05-1870-g05){#f6-ijo-49-05-1870}

###### 

Characteristics of the lung cancer and non-cancerous cases.

  A, Characteristics of the lung cancer cases                   
  ----------------------------------------------- ------------- --------
  Total no                                        31            
  Median age (range)                              70 (50--88)   
  Gender                                                        
   Male                                           29            (93.5)
   Female                                         2             (6.5)
  Pathological stage                                            
   IA                                             4             (12.9)
   IB                                             9             (29.0)
   IIA                                            4             (12.9)
   IIB                                            5             (16.1)
   IIIA                                           8             (25.8)
   IIIB                                           1             (3.2)
                                                                
  B, Characteristics of the non-cancerous cases                 
                                                                
  Non-cancerous tissues                           n             
                                                                
  Total number                                    24            
  Median age (range)                              69 (50--88)   
  Gender                                                        
   Male                                           24            
   Female                                         0             

###### 

Downregulated genes in *miR-218* tranfectant.

  Entrez gene ID   Gene symbol   Description                                                         *miR-218* target site   EBC-1 *miR-218* transfectant (log~2~ ratio)   GSE: 19188 (fold change)           
  ---------------- ------------- ------------------------------------------------------------------- ----------------------- --------------------------------------------- -------------------------- ------- -------
  7163             *TPD52*       Tumor protein D52                                                   4                       2                                             2                          −1.33   2.66
  5563             *PRKAA2*      Protein kinase, AMP-activated, α 2 catalytic subunit                4                       0                                             4                          −1.04   2.50
  2673             *GFPT1*       Glutamine-fructose-6-phosphate transaminase 1                       4                       1                                             3                          −1.17   1.92
  332              *BIRC5*       Baculoviral IAP repeat containing 5                                 2                       0                                             2                          −2.05   12.42
  56938            *ARNTL2*      Aryl hydrocarbon receptor nuclear translocator-like 2               2                       0                                             2                          −1.09   7.85
  112399           *EGLN3*       Egl-9 family hypoxia-inducible factor 3                             2                       1                                             1                          −1.45   5.97
  84181            *CHD6*        chromodomain helicase DNA binding protein 6                         2                       1                                             1                          −1.35   2.30
  29927            *SEC61A1*     Sec61 α 1 subunit (*S. cerevisiae*)                                 2                       1                                             1                          −1.09   2.13
  8776             *MTMR1*       Myotubularin related protein 1                                      2                       1                                             1                          −1.06   1.96
  131566           *DCBLD2*      Discoidin, CUB and LCCL domain containing 2                         2                       2                                             0                          −1.46   1.88
  2820             *GPD2*        Glycerol-3-phosphate dehydrogenase 2 (mitochondrial)                2                       0                                             2                          −1.02   1.83
  399694           *SHC4*        SHC (Src homology 2 domain containing) family, member 4             2                       1                                             1                          −1.25   1.58
  3486             *IGFBP3*      Insulin-like growth factor binding protein 3                        1                       0                                             1                          −2.09   4.12
  144406           *WDR66*       WD repeat domain 66                                                 1                       0                                             1                          −1.11   2.98
  25907            *TMEM158*     Transmembrane protein 158 (gene/pseudogene)                         1                       0                                             1                          −1.12   2.96
  10447            *FAM3C*       Family with sequence similarity 3, member C                         1                       1                                             0                          −2.08   2.90
  4017             *LOXL2*       Lysyl oxidase-like 2                                                1                       0                                             1                          −1.96   2.56
  9139             *CBFA2T2*     Core-binding factor, runt domain, α subunit 2; translocated to, 2   1                       0                                             1                          −1.11   2.42
  3691             *ITGB4*       Integrin, β 4                                                       1                       0                                             1                          −1.12   2.20
  6745             *SSR1*        Signal sequence receptor, α                                         1                       1                                             0                          −1.47   1.92
  1457             *CSNK2A1*     Casein kinase 2, α 1 polypeptide                                    1                       1                                             0                          −1.30   1.90
  157638           *FAM84B*      Family with sequence similarity 84, member B                        1                       0                                             1                          −1.02   1.90
  949              *SCARB1*      Scavenger receptor class B, member 1                                1                       0                                             1                          −1.54   1.84
  2011             *MARK2*       MAP/microtubule affinity-regulating kinase 2                        1                       1                                             0                          −1.41   1.75
  9289             *GPR56*       G protein-coupled receptor 56                                       1                       0                                             1                          −1.53   1.70
  55959            *SULF2*       Sulfatase 2                                                         1                       0                                             1                          −1.11   1.67
  65985            *AACS*        Acetoacetyl-CoA synthetase                                          1                       0                                             1                          −1.10   1.63
  160              *AP2A1*       Adaptor-related protein complex 2, α 1 subunit                      1                       1                                             0                          −1.14   1.63
  54928            *IMPAD1*      Inositol monophosphatase domain containing 1                        1                       1                                             0                          −1.01   1.62
  1889             *ECE1*        Endothelin converting enzyme 1                                      1                       0                                             1                          −1.55   1.61
  55609            *ZNF280C*     Zinc finger protein 280C                                            1                       1                                             0                          −1.10   1.61
  6533             *SLC6A6*      Solute carrier family 6 (neurotransmitter transporter), member 6    1                       1                                             0                          −1.13   1.61
  80000            *GREB1L*      Growth regulation by estrogen in breast cancer-like                 1                       0                                             1                          −1.15   1.59
  10776            *ARPP19*      cAMP-regulated phosphoprotein, 19 kDa                               1                       1                                             0                          −1.33   1.52
  83637            *ZMIZ2*       Zinc finger, MIZ-type containing 2                                  1                       1                                             0                          −1.59   1.52
  79139            *DERL1*       Derlin 1                                                            1                       0                                             1                          −1.16   1.51

###### 

Immunohistochemistry status and characteristics of the lung cancer and non-cancerous cases.

  A, Immunohistochemistry status and characteristics of the lung squamous cell carcinoma cases                                             
  ---------------------------------------------------------------------------------------------- ---------------------- --- --- --- ------ -------
  1                                                                                              1                      3   1   0   IIIa   (++)
  2                                                                                              1                      3   0   0   IIIa   (++)
  3                                                                                              2                      2   1   0   II     (++)
  4                                                                                              2                      3   0   0   IIIa   (++)
  5                                                                                              1                      2   0   0   I      (++)
  6                                                                                              1                      2   1   0   II     (+)
  7                                                                                              1                      3   1   0   IIIa   (+++)
  8                                                                                              1                      2   0   0   I      (++)
  9                                                                                              1                      2   1   0   II     (++)
  10                                                                                             1                      2   0   0   I      (++)
  11                                                                                             2                      2   2   0   IIIa   (+++)
  12                                                                                             2                      2   0   0   I      (+)
  13                                                                                             2                      1   0   0   I      (++)
  14                                                                                             2                      1   0   0   I      (++)
  15                                                                                             2                      2   1   0   II     (+)
  16                                                                                             2                      3   1   0   III    (++)
  17                                                                                             2                      2   0   0   I      (++)
  18                                                                                             2                      2   1   0   II     (+)
  19                                                                                             2                      3   2   0   IIIa   (+++)
  20                                                                                             2                      2   0   0   I      (++)
                                                                                                                                           
  B, Immunohistochemistry status of non-cancerous cases                                                                                    
                                                                                                                                           
  Patient no.                                                                                    Immunohistochemistry                      
                                                                                                                                           
  91                                                                                             (−)                                       
  92                                                                                             (+)                                       
  93                                                                                             (+)                                       
  94                                                                                             (−)                                       
  95                                                                                             (−)                                       
  96                                                                                             (−)                                       
  97                                                                                             (−)                                       
  98                                                                                             (+)                                       
  99                                                                                             (+)                                       
  100                                                                                            (+)                                       

###### 

Significantly enriched annotations regulated by si-*TPD52*-1 and si-*TPD52*-2 in lung SCC cells.

  No. of genes   P-value    Annotations
  -------------- ---------- -------------------------------------------------------
  12             2.06E-11   (KEGG) 04110: Cell cycle
  8              8.84E-07   (KEGG) 04114: Oocyte meiosis
  7              2.27E-06   (KEGG) 05322: Systemic lupus erythematosus
  5              5.41E-06   (KEGG) 03030: DNA replication
  6              2.30E-05   (KEGG) 04914: Progesterone-mediated oocyte maturation
  5              9.53E-05   (KEGG) 04115: p53 signaling pathway
  2              4.91E-02   (KEGG) 03410: Base excision repair

###### 

Representative pathways identified as downstream of *TPD52*.

  Cell cycle pathway                                                                  
  ------------------------- --------------------------------------------------------- --------------------------
  *TTK*                     TTK protein kinase                                        3.23
  *BUB1*                    Budding uninhibited by benzimidazoles 1 homolog (yeast)   3.21
  *CCNB2*                   Cyclin B2                                                 3.20
  *MCM4*                    Minichromosome maintenance complex component 4            3.13
  *CCNB1*                   Cyclin B1                                                 2.82
  *PLK1*                    Polo-like kinase 1                                        2.81
  *CDC25C*                  Cell division cycle 25 homolog C (*S. pombe*)             2.77
  *CDK1*                    Cyclin-dependent kinase 1                                 2.40
  *CCNE2*                   Cyclin E2                                                 2.04
  *DBF4*                    DBF4 homolog (*S. cerevisiae*)                            1.42
  *MCM6*                    Minichromosome maintenance complex component 6            1.31
  *BUB3*                    Budding uninhibited by benzimidazoles 3 homolog (yeast)   1.07
                                                                                      
  DNA replication pathway                                                             
                                                                                      
  Gene symbol               Description                                               GSE:19188 (log~2~ ratio)
                                                                                      
  *MCM4*                    Minichromosome maintenance complex component 4            3.13
  *FEN1*                    Flap structure-specific endonuclease 1                    1.66
  *MCM6*                    Minichromosome maintenance complex component 6            1.31
  *PRIM1*                   Primase, DNA, polypeptide 1 (49 kDa)                      1.25
  *POLA2*                   Polymerase (DNA directed), α 2 (70 kD subunit)            1.00
                                                                                      
  p53 signaling pathway                                                               
                                                                                      
  Gene symbol               Description                                               GSE:19188 (log~2~ ratio)
                                                                                      
  *CCNB2*                   Cyclin B2                                                 3.20
  *CCNB1*                   Cyclin B1                                                 2.82
  *GTSE1*                   G-2 and S-phase expressed 1                               2.79
  *CDK1*                    Cyclin-dependent kinase 1                                 2.40
  *CCNE2*                   Cyclin E2                                                 2.04
